SCOLR Expects New Licensing Agreement This Year
This article was originally published in The Tan Sheet
Executive Summary
SCOLR Pharma says it could have a new licensing agreement for an extended release ibuprofen product made with its patented Controlled Delivery Technology by September of this year
You may also be interested in...
SCOLR Ready To Answer FDA Questions On 12-Hour Pseudoephedrine ANDA
FDA has raised questions on "minor" issues regarding SCOLR Pharma's proposed nonprescription 12-hour pseudoephedrine tablet, according to the firm
SCOLR’s Extended-Release Ibuprofen Plans Ramp Up After Break With Wyeth
SCOLR Pharma plans to submit a new drug application for its extended-release ibuprofen to FDA in the latter half of 2008
SCOLR May File NDA For Ibuprofen Product Following Break With Wyeth
SCOLR Pharma will either file an NDA with FDA or work with another pharmaceutical company to develop its 12-hour extended-release ibuprofen product after Wyeth announced it will terminate an agreement with the firm effective April 16